Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.45 |
| ▸ | SQLE | Q14534 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lycopene SCHEMBL710317 | 1.00 | NR1I2 (1.00) | NR1I2LMNAPGRALDH1A1KMT2A | |
| SCHEMBL2833787 | 1.00 | NR1I2 (1.00) | NR1I2LMNAPGRALDH1A1KMT2A | |
| Lycopene SCHEMBL29725051 | 1.00 | NR1I2 (1.00) | NR1I2LMNAPGRALDH1A1KMT2A | |
| Lycopene SCHEMBL4538742 | 1.00 | NR1I2 (1.00) | NR1I2LMNAPGRALDH1A1KMT2A | |
| Lycopene SCHEMBL20158 | 1.00 | NR1I2 (1.00) | NR1I2LMNAPGRALDH1A1KMT2A | |
| Lycopene SCHEMBL30471634 | 1.00 | NR1I2 (1.00) | NR1I2LMNAPGRALDH1A1KMT2A | |
| Lycopene SCHEMBL38650730 | 1.00 | NR1I2 (1.00) | NR1I2LMNAPGRALDH1A1KMT2A | |
| Lycopene SCHEMBL30272252 | 1.00 | NR1I2 (1.00) | NR1I2LMNAPGRALDH1A1KMT2A | |
| Lycopene SCHEMBL21485499 | 1.00 | NR1I2 (1.00) | NR1I2LMNAPGRALDH1A1KMT2A | |
| Lycopene SCHEMBL1423405 | 1.00 | NR1I2 (1.00) | NR1I2LMNAPGRALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260026443-A1 | METHODS FOR ENHANCING BIOACTIVE PHYTOCHEMICALS | TEXAS A & M UNIV SYS (US) | 2026-01-29 | — | — | US | claimed |
| CN-117326911-A | A method for promoting lycopene to undergo cis-isomerization by using food ingredients | 江南大学 | 2024-01-02 | — | — | CN | claimed |
| CN-117179273-A | Method for preparing and processing high-cis-lycopene-content product from tomato sour soup oil | 贵州大学 | 2023-12-08 | — | — | CN | claimed |
| EP-4216925-A1 | PARENTERAL NUTRITION FORMULATION COMPRISING VITAMIN B12 | Baxter International Inc. (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2023120618-A1 | CIS-CAROTENOID-CONTAINING EMULSION COMPOSITION, AND METHOD FOR PRODUCING CIS-CAROTENOID-CONTAINING EMULSION COMPOSITION | 学校法人名城大学 | 2023-06-29 | — | — | WO | claimed |
| CN-116217334-A | Lycopene crystal and preparation method and application thereof | 晨光生物科技集团股份有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-116018135-A | Parenteral nutritional formulation comprising vitamin B12 | 巴克斯特国际公司 | 2023-04-25 | — | — | CN | claimed |
| CN-115606802-A | Application of lycopene in preparation of product for repairing intestinal barrier injury | 中国农业大学 | 2023-01-17 | — | — | CN | claimed |
| CN-115554281-A | Application of lycopene in preparation of product for improving symptoms of non-alcoholic steatohepatitis | 中国农业大学 | 2023-01-03 | — | — | CN | claimed |
| US-20220351865-A1 | METHODS OF BIOLOGICAL AGE EVALUATION AND SYSTEMS USING SUCH METHODS | GERO PTE. LTD. (SG) | 2022-11-03 | — | — | US | claimed |
| WO-2022063963-A1 | PARENTERAL NUTRITION FORMULATION COMPRISING VITAMIN B12 | BAXTER INTERNATIONAL INC. (US) | 2022-03-31 | — | — | WO | claimed |
| EP-3973950-A1 | PARENTERAL NUTRITION FORMULATION COMPRISING VITAMIN B12 | Baxter International Inc (US) | 2022-03-30 | — | — | EP | claimed |
| CN-121949050-A | Efficient and stable lycopene isomerization method | 中国药科大学 | 2026-05-01 | — | — | CN | disclosed |
| US-20260083806-A1 | Heart boosting formulation and related methods of manufacture | PRASAD KEDAR (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260026443-A1 | METHODS FOR ENHANCING BIOACTIVE PHYTOCHEMICALS | TEXAS A & M UNIV SYS (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260026443-A1 | METHODS FOR ENHANCING BIOACTIVE PHYTOCHEMICALS | TEXAS A & M UNIV SYS (US) | 2026-01-29 | — | — | US | disclosed |
| US-11273138-B2 | Use of amino acid supplementation for improved muscle protein synthesis | BIOVENTURES, LLC (US) | 2022-03-15 | — | — | US | disclosed |
| CN-110128234-B | Quick green preparation method of high cis-isomer lycopene | 新疆红帆生物科技有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-109700025-B | Preparation method of lycopene oil suspension and oil suspension thereof | 晨光生物科技集团股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-109700025-B | Preparation method of lycopene oil suspension and oil suspension thereof | 晨光生物科技集团股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083806-A1 | Heart boosting formulation and related methods of manufacture | LPL, CRAT, LCLAT1 | NR1I2 2613/4885LMNA 138/4885PGR 3649/4885 |
| US-20260026443-A1 | METHODS FOR ENHANCING BIOACTIVE PHYTOCHEMICALS | LSS, ALAD, CYBA | NR1I2 3152/4885LMNA 288/4885PGR 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.